BioNTech SE
trastuzumab pamirtecan
endometrial cancer
Resolved
87days ago
Phase 2 readout · Apr 11, 2026
What's at stake
Phase 2 trial results for trastuzumab pamirtecan in endometrial cancer are due Apr 11, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 11h ago
“BioNTech today announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan (BNT323/DB-1303) in patients with HER2-expressing, advanced endometrial cancer whose disease progressed on or after fi”